Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
The shot has been approved to be given at least five months after the two-dose primary series, CNBC reported. It was authorized because data showed that COVID protection weakens over time following ...